These 10 corporations represent 37% of the MEA market by value. Novo Nordisk’s USD 635M growth is mainly driven by Norditropin (somatropin), Victoza (liraglutide) & Saxenda (liraglutide) which have grown at 60%, 18% and 190% PPG respectively. Hikma’s USD 497M growth has been the fastest due to Remox (amoxicillin) and Pranza (olanzapine), growing at 108% and 477% PPG respectively.  

Made with Visme Infographic Maker